Value proposition Value Genome positions itself as a specialized partner for biotech firms aiming to accelerate value realization through early integration of clinical and economic evidence, creating a compelling case for reimbursement, licensing, or market entry.

Target customer Primary opportunities are oncology and rare disease companies seeking strategic guidance on market access, HEOR, medical affairs, and payer/KOL engagement to optimize asset value and negotiations with payers and potential acquirers.

Market positioning As a boutique collaboration of former pharma executives with payer and KOL networks, Value Genome can offer differentiated access to stakeholders and tailored value narratives, appealing to mid-size to specialty biotech firms needing credible, evidence-driven messaging.

Expansion prospects Potential sales expansions include offering end-to-end value dossiers, health economics modeling, real-world data strategies, and advocacy engagement services to support asset valuation, pricing, and reimbursement discussions across markets.

Digital enablement Leverage their tech stack and digital outreach capabilities to scale outreach to biotech clients, deliver customizable value communication packages, and track engagement metrics with payers, KOLs, and regulatory bodies.